Lurbinectedin is a new drug that is used in combination with other drugs to treat small cell lung cancer (SCLC) [1]. The combination of lurbinectedin with other drugs has shown promising results in clinical trials, but like any other drug, it may have some side effects.

According to a study published in the National Library of Medicine, the most common side effects of lurbinectedin in combination with doxorubicin are low white blood cell count, fatigue, nausea, and vomiting [2]. Another study published in the American Cancer Society has also reported that the combination of lurbinectedin with other drugs may cause low white blood cell count, fatigue, and nausea [3].

It is important to note that these side effects are not unique to lurbinectedin and can occur with other chemotherapy drugs as well. However, if these side effects become severe or persistent, patients should contact their healthcare provider immediately.

In conclusion, while lurbinectedin in combination with other drugs has shown promising results in treating SCLC, it may cause some side effects. Patients should be aware of these potential side effects and contact their healthcare provider if they experience any severe or persistent symptoms.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900004/
[3] https://www.cancer.org/cancer/types/lung-cancer/treating-small-cell/chemotherapy.html